Artiva Biotherapeutics (ARTV) Cash from Operations (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash from Operations data on file, last reported at 20950000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 5.59% year-over-year to 20950000.0 in Q1 2026; TTM through Mar 2026 was 77909000.0, a 30.31% decrease from a year earlier, with the FY2025 full-year figure at 76800000.0, down 39.56% from the prior year.
• Cash from Operations for Q1 2026 stood at 20950000.0, down from 14775000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ARTV reached as high as 10675000.0 in Q4 2023 and fell as low as 22983000.0 in Q2 2025.
• Historically, Cash from Operations has averaged 15836818.18 across 4 years, with a median of 14775000.0 in 2025.
• On a YoY basis, Cash from Operations climbed as much as 0.85% in 2025 and fell as far as 67.94% in 2025.
• Year by year, Cash from Operations stood at 10675000.0 in 2023, then plunged by 37.24% to 14650000.0 in 2024, then declined by 0.85% to 14775000.0 in 2025, then tumbled by 41.79% to 20950000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 20950000.0 in Q1 2026, 14775000.0 in Q4 2025, and 19201000.0 in Q3 2025.